Source and scope
This summary is bounded to the recommendations, population and decisions covered by Pharmacological management of chronic neuropathic pain: revised consensus statement. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:CPS neuropathic pain
Source-attributed clinical priorities
- Identify a plausible lesion or disease of the somatosensory system and document sensory findings rather than diagnosing from descriptors alone.
- Treat reversible causes and match first-line medication to comorbidity, interactions, renal function and adverse-effect risk.
- Use function and pain interference as outcomes, titrate one intervention at a time and stop ineffective treatment.
- Map sensory loss, allodynia and weakness to a plausible neuroanatomic distribution before calling pain neuropathic.
sources for this section:CPS neuropathic pain
Practical assessment and management workflow
1
Establish cause, tempo and distribution and examine strength, reflexes, sensation, gait and skin integrity.
2
Investigate diabetes, alcohol, vitamin deficiency, renal disease, infection, compression or medication causes selectively.
3
Choose one first-line agent around sleep, mood, renal function, falls and interaction risks.
4
Titrate to a predefined trial, measure function and pain interference, and taper if benefit is not meaningful.
sources for this section:CPS neuropathic pain
Safety, red flags and urgent escalation
- Rapid asymmetric weakness, sphincter change or a new sensory level requires urgent neurologic assessment.
- Review sedation and driving risk and avoid dangerous combinations with opioids or alcohol.
- Protect insensate skin and feet from thermal injury, pressure and unnoticed wounds.
sources for this section:CPS neuropathic pain
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:CPS neuropathic pain
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:CPS neuropathic pain
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Canadian Pain SocietyPharmacological management of chronic neuropathic pain: revised consensus statementaccessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.